Assessment of cetuximab efficacy by bioluminescence monitoring of intracranial glioblastoma xenograft in mouse

Journal of Neuro-Oncology

Volumn 95, Issue 1, 2009, Pages 23-28

  Yang, Seung Ho ^a   Hong, Yong Kil ^b   Jeun, Sin Soo ^b   Kim, Il Sup ^b   Hong, Jae Taek ^a   Sung, Jae Hoon ^a   Son, Byung Chul ^a   Lee, Sang Won ^a   Kim, Moon Chan ^b   Lee, Kwan Sung ^b  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

Bioluminescence imaging; Cetuximab; Epidermal growth factor receptor; Glioblastoma multiforme; Target therapy

Indexed keywords

CETUXIMAB; LOMUSTINE;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLUMINESCENCE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; GLIOBLASTOMA; HUMAN; HUMAN CELL; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PREDICTION; SALVAGE THERAPY; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; DISEASE MODELS, ANIMAL; GLIOBLASTOMA; LOMUSTINE; LUMINESCENCE; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; SURVIVAL ANALYSIS; TIME FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 70349333060     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-009-9895-3     Document Type: Article

References (22)

1. Stewart LA (2002) Chemotherapy in adult high-grade gliomas: A systematic review and meta-analysis of individual patient data from 12 randomized trials. Lancet 359:1011-1018. doi: 10.1016/S0140-6736(02)08091-1
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organization for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups National Cancer Institute of Canada Clinical Trial Group (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996. doi: 10.1056/NEJMoa043330
3. Smith JS, Tachibana I, Passe SM, Huntley BK, Borell TJ, Iturria N, O'Fallon JR, Schaefer PL, Scheithauer BW, James CD, Buckner JC, Jenkins RB (2001) PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 93:1246-1256. doi: 10.1093/jnci/93.16.1246
4. Nathoo N, Goldlust S, Vogelbaum MA (2004) Epidermal growth factor receptor antagonists: Novel therapy for the treatment of high-grade gliomas. Neurosurgery 54:1480-1488. doi: 10.1227/ 01.NEU.0000125006.88478.F6
5. Eller JL, Longo SL, Hicklin DJ, Canute GW (2002) Activity of anti-EGFR monoclonal antibody C225 against glioblastoma multiforme. Neurosurgery 51:1005-1014. doi: 10.1097/00006123-200210000-00028
6. McElroy WD (1951) Properties of the reaction utilizing adenosine triphosphate for bioluminescence. J Biol Chem 191:547-557
7. Szentirmai O, Baker CH, Lin N, Szucs S, Takahashi M, Kiryu S, Kung AL, Mulligan RC, Carter BS (2006) Noninvasive bioluminescence imaging of luciferase expressing intracranial U87 xenograft: Correlation with magnetic resonance imaging determined tumor volume and longitudinal use in assessing tumor growth and antiangiogenic treatment effect. Neurosurgery 58:365-372. doi: 10.1227/01.NEU.0000195114.24819.4F
8. Belda-Iniesta C, Carpeño Jde C, Saenz EC, Gutiérrez M, Perona R, Barón MG (2006) Long term responses with cetuximab therapy in glioblastoma multiforme. Cancer Biol Ther 5:912-914
9. Combs SE, Heeger S, Haselmann R, Edler L, Debus J, Schulz-Ertner D (2006) Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide phase I/II study: Study protocol. BMC Cancer 6:133. doi: 10.1186/1471-2407-6-133
10. Blick SK, Scott LJ (2007) Cetuximab: A review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer. Drugs 67:2585-2607. doi: 10.2165/00003495-200767170-00008
11. Eller JL, Longo SL, Kyle MM, Bassano D, Hichlin DJ, Canute GW (2005) Anti-epidermal growth factor receptor monoclonal antibody cetuximab augments radiation effects in glioblastoma multiforme in vitro and in vivo. Neurosurgery 56:155-162
12. Stragliotto G, Vega F, Stasiecki P, Gropp P, Poisson M, Delattre JY (1996) Multiple infusion of anti-epidermal growth factor receptor monoclonal antibody (EMD 55, 900) in patients with recurrent malignant gliomas. Eur J Cancer 32:636-640. doi: 10.1016/0959-8049(95)00592-7
13. Omuro AMP, Faivre S, Raymond E (2007) Lessons learned in the development of targeted therapy for malignant gliomas. Mol Cancer Ther 6:1909-1919. doi: 10.1158/1535-7163.MCT-07-0047
14. Combs SE, Schulz-Ertner D, Roth W, Herold-Mende C, Debus J, Weber KJ (2007) In vitro responsiveness of glioma cell lines to multimodality treatment with radiotherapy, temozolomide, and epidermal growth factor receptor inhibition with cetuximab. Int J Radiat Oncol Biol Phys 68:873-882. doi: 10.1016/j.ijrobp.2007.03.002
15. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345. doi: 10.1056/NEJMoa033025
16. Knecht R, Peters S, Adunka O, Strebhardt K, Gstoettner W, Hambek M (2003) Carcinomas unresponsive to either cisplatinum or anti-EGFR therapy can be growth inhibited by combination therapy of both agents. Anticancer Res 23:2577-2583
17. Dancey J (2004) Epidermal growth factor receptor inhibitors in clinical development. Int J Radiat Oncol Biol Phys 58:1003-1007. doi: 10.1016/ j.ijrobp.2003.07.011
18. Adams GP, Weiner LM (2005) Monoclonal antibody therapy of cancer. Nat Biotechnol 23:1147-1157. doi: 10.1038/nbt1137
19. Brandes AA, Franceschi E, Tosoni A, Hegi ME, Stupp R (2008) Epidermal growth factor receptor inhibitors in neuro-oncology: Hopes and disappointments. Clin Cancer Res 14:957-960. doi: 10.1158/ 1078-0432.CCR-07-1810
20. Contag CH, Bachmann MH (2002) Advances in in vivo bioluminescence imaging of gene expression. Annu Rev Biomed Eng 4:235-260. doi: 10.1146/ annurev.bioeng.4.111901.093336
21. Shah K, Bureau E, Kim DE, Yang K, Tang Y, Weissleder R, Breakefield XO (2005) Glioma therapy and real-time imaging of neural precursor cell migration and tumor regression. Ann Neurol 57:34-41. doi: 10.1002/ ana.20306
22. Dinca E, Sarkaria JN, Schroeder MA, Carlson BL, Voicu R, Gupta N, Berger MS, James CD (2007) Bioluminescence monitoring of intracranial glioblastoma xenograft: Response to primary and salvage temozolomide therapy. J Neurosurg 107:610-616. doi: 10.3171/JNS-07/09/0610